Academic Journal
Glucagon stimulation test to assess growth hormone status in Prader–Willi syndrome
| العنوان: | Glucagon stimulation test to assess growth hormone status in Prader–Willi syndrome |
|---|---|
| المؤلفون: | Casamitjana, L., Giménez-Palop, O., Corripio, R., Pareja, R., Berlanga, E., Rigla, M., Oliva, JC., Caixàs, A. |
| المساهمون: | Instituto de Salud Carlos III, Pfizer Foundation |
| المصدر: | Journal of Endocrinological Investigation ; volume 44, issue 3, page 621-629 ; ISSN 1720-8386 |
| بيانات النشر: | Springer Science and Business Media LLC |
| سنة النشر: | 2020 |
| الوصف: | Purpose Growth hormone deficiency (GHD) must be confirmed before starting treatment in adults with Prader-Willi syndrome (PWS). Most studies use the growth-hormone-releasing hormone plus arginine (GHRH-arginine) test. No data are available on the glucagon stimulation test (GST) in PWS. We compared the utility of fixed-dose (1 mg) GST versus GHRH-arginine test in diagnosing GHD. Methods Adults and late adolescents with PWS underwent both tests on separate days. In the GHRH-arginine test, GHD was defined according to body mass index. In the GST, two cutoffs were analyzed: peak GH concentration < 3 ng/mL and < 1 ng/mL. For analyses, patients were divided into two groups according to body weight (≤ 90 kg and > 90 kg). Results We analyzed 34 patients: 22 weighing ≤ 90 kg and 12 weighing > 90 kg. In patients weighing ≤ 90 kg, the two tests were concordant in 16 (72.72%) patients ( k = 0.476, p = 0.009 with GST cutoff < 3 ng/mL, and k = 0.450, p = 0.035 with GST cutoff < 1 ng/mL). In patients weighing > 90 kg, the two tests were not concordant with GST cutoff < 3 ng/mL, but were concordant in 11 (91.6%) patients ( k = 0.833, p = 0.003) with GST cutoff < 1 ng/mL. GH peaks on the two tests correlated ( r = 0.725, p = 0.008). Conclusion Fixed-dose (1 mg) GST using a peak GH cutoff of < 3 ng/mL or < 1 ng/mL promises to be useful for screening for GHD in adults and late adolescents with PWS. However, in those weighing > 90 kg, the < 1 ng/mL cutoff seems better. Larger studies are necessary to establish definitive glucagon doses and cutoffs, especially in extremely obese patients. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1007/s40618-020-01367-6 |
| DOI: | 10.1007/s40618-020-01367-6.pdf |
| DOI: | 10.1007/s40618-020-01367-6/fulltext.html |
| الاتاحة: | http://dx.doi.org/10.1007/s40618-020-01367-6 https://link.springer.com/content/pdf/10.1007/s40618-020-01367-6.pdf https://link.springer.com/article/10.1007/s40618-020-01367-6/fulltext.html |
| Rights: | https://creativecommons.org/licenses/by/4.0 ; https://creativecommons.org/licenses/by/4.0 |
| رقم الانضمام: | edsbas.B168B63A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s40618-020-01367-6 |
|---|